Abexinostat (PCI-24781, CRA-024781, PCI24781, CRA024781)，又称阿贝司他或艾贝司他，是含异羟肟酸的pan-HDAC抑制剂，作用于HDAC1的K_i为7 nM，属于非细胞周期特异性的细胞毒性药物，对多种肿瘤细胞具有抗肿瘤效果。目前，Abexinostat处于治疗肾细胞癌的III期临床试验中。

参考文献

[1] Buggy JJ, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309-17.

[2] Adimoolam S, et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Free Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7.

[3] Lechner S, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Aug;18(8):812-820.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。